Can a Smaller Plasmid Produce Huge Benefits? The Power of Small

WATCH NOW | MEET THE PANEL
Access the information from the slides here

Optimizing gene payload begins with plasmid design.

That’s where the Nanoplasmid™ vector platform has shown benefits over traditional plasmids. The small (<500bp) backbone reduces potential plasmid silencing in target cells and tissues compared to plasmids containing up to 1.5–2kb of bacterial regions and junk DNA.

With benefits across applications including transposons, HDR/CRISPR, viral vectors, and mRNA; nanoplasmids are designed to replace antiquated bacterial backbones, while eliminating antibiotic marker that can cause regulatory concerns.

Join us for a discussion on how nanoplasmid benefits may accelerate therapies.

WHAT TO EXPECT

Part 1: The panel will address the unique opportunities associated with using nanoplasmids over traditional plasmids (dependent on application), including:

• AAV application: safety benefits.
• Lentiviral application: significant increase in viral titres and additional safety benefits.
• Cell therapy: reduced cell death which leads to improved performance and longevity.

Part 2: The panel answers audience questions with an interactive Q&A.

MEET THE PANEL

Jim Williams
Chief Scientific Officer, VP R&D
Nature Technology Corporation

Emma Bjorgum
VP, DNA Client Services
Aldevron

Ellen Shafer
Senior Director of Marketing & Communications
Aldevron

Tyler Koziek
Research and Development Scientist
Aldevron

This content is brought to you in partnership with Phacilitate and Aldevron, who are independent but joint controllers. You may receive follow up communications from Phacilitate and Aldevron with information directly related to this content, and you will be able to opt out from being contacted by using the unsubscribe links in these emails.